Gene-Editing Therapeutics Market Growth, Demand and Production Forecast 2035
According to market projection, the gene-editing therapeutics market is entering a rapid expansion phase, rising from USD 2.47 billion in 2026 to USD 18.15 billion by 2035 at a 24.80% CAGR. Research identifies CRISPR/Cas, ex-vivo edited cell therapies, and genetic and rare disease applications as the market's leading segments, while base/prime editing, in-vivo therapeutics, cardiovascular applications, and LNP-based delivery systems are gaining momentum. North America maintains market leadership, Asia Pacific records the fastest growth, and innovation from companies including CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, and Verve Therapeutics continues to shape the competitive landscape.
Last Updated : 19 August 2026Category: Therapeutic AreaInsight Code: 6079Format: PDF / PPT / Excel
Market Size, Forecast & CAGR, By Segment 1, 2022-2035
Key Rationale
Y-o-Y Analysis
Global XX Market Analysis, By Segment 2
Market Size, Forecast & CAGR, By Segment 1, 2022-2035
Key Rationale
Y-o-Y Analysis
Global XX Market Analysis, By Segment 3
Market Size, Forecast & CAGR, By Segment 1, 2022-2035
Key Rationale
Y-o-Y Analysis
Global XX Market Analysis, By Region
Market Size, Forecast & CAGR, By Segment 1, 2022-2035
Key Rationale
Y-o-Y Analysis
North America XX Market Analysis
North America XX Market Analysis, By Segment 1, 2022-2035
Key Rationale
Y-o-Y Analysis
North America XX Market Analysis, By Segment 2, 2022-2035
Key Rationale
Y-o-Y Analysis
North America XX Market Analysis, By Segment 2, 2022-2035
Key Rationale
Y-o-Y Analysis
North America XX Market Analysis, By Country, 2022-2035
Key Rationale
Y-o-Y Analysis
U.S. XX Market Analysis
U.S. XX Market Analysis, By Segment 1, 2022-2035
Key Rationale
Y-o-Y Analysis
U.S. XX Market Analysis, By Segment 2, 2022-2035
Key Rationale
Y-o-Y Analysis
U.S. XX Market Analysis, By Segment 3, 2022-2035
Key Rationale
Y-o-Y Analysis
Similar Analysis will be given for each country and each region
Canada
Mexico
Rest of North America
Europe
Western Europe
Germany
Italy
France
Spain
UK
Netherlands
Switzerland
Nordic Countries
Rest of Western Europe
Eastern Europe
Austria
Russia & Belarus
Poland
Türkiye
Rest of Eastern Europe
Asia Pacific
China
Taiwan
India
Japan
Vietnam
Australia and New Zealand
ASEAN Countries
South Korea
Rest of APAC
South America
Brazil
Argentina
Rest of South America
Middle East and Africa (MEA)
GCC Countries
South Africa
Egypt
Rest of MEA
Chapter 7: Competitive Insights
Competitive Analysis
Company Evaluation Matrix
Major Players
Mid-Sized Companies
Emerging Players/Start-Ups
Global Market Share Analysis, By Region, 2025 (%)
Key Player Positioning
Competitive Benchmarking
By Segment 1
By Segment 2
By Segment 3
Strategies of Key Players
Insight From the Horse’s Mouth
Company Profiles
Company 1
Company Name
Company Headquarters
Management Overview
Key C-Suite Executives
CEO
MD
Others
Employee Count
Business Strategy
Key Investments Made
Future Plans
R&D & Innovation Capabilities
Recent Developments
New Product Launch
Merger & Acquisitions
Partnerships & Collaborations
Market Expansion
Others
Service Portfolio
Facility Network
Number of Facilities
Bed Capacity
Facility Distribution
Expansion Pipeline
Key Financials (2022-2025)
Revenue By Segment
Revenue By Service
Revenue By Geography
Financial Matrix (Gross Profit Margins, Net Margins, etc.)
Key Clients
Client Company Name
Key Contact Person
Contact Details
Regulatory & Certification Expertise
SWOT Analysis
FAQ's
Answer : The gene editing therapeutics market stands at USD 2.47 billion in 2026 and is expected to reach USD 18.15 billion by 2035, growing at a CAGR of 24.80% from 2026 to 2035.
Answer : North America is currently leading the gene-editing therapeutics market by 48% share due to the presence of the largest cluster of sponsors.
Answer : Some key players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Beam Therapeutics.
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare
market research. As a content reviewer, Aditi ensures the quality and accuracy of all market
insights and data presented by the research team.
We use cookies that are necessary to make our site work. We may also use additional cookies to analyze,
improve, and personalize our content and your digital experience.
You can manage your cookie preferences using the
Privacy Policy
For more information, see our
Terms and Conditions
.
Cookie Preference Center
We use cookies which are necessary to make our site work.
We may also use additional cookies to analyze, improve and personalize
our content and your digital experience.
For more information, please read our
Cookie Policy
.
You may choose not to allow some types of cookies.
Blocking some cookies may impact your experience of the site.
sales@towardshealthcare.com
+1 804-441-9344
Download Sample
USA : +1 8044 419344
sales@towardshealthcare.com